Allele

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Friday, April 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, April 4, 2024
Research, Virtual, NSCLC, Immunotherapy, TIL, Patient, G&A, Allele, ACHL, HLA, Neoplasm, Therapy, Event, Safety, Melanoma, Patent, Escape Room, Cryptocurrency

LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Key Points: 
  • These learnings will inform the development of cNeT and related neoantigen vaccine and TCR-T therapies,” said Dr Iraj Ali, Chief Executive Officer of Achilles Therapeutics.
  • Research and development (R&D) expenses: R&D expenses were $15.9 million for the fourth quarter ended December 31, 2023, a decrease of $3.0 million compared to $18.9 million for the fourth quarter ended December 31, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $3.6 million for the fourth quarter ended December 31, 2023, a decrease of $0.4 million compared to $4.0 million for December 31, 2022.
  • Net loss: Net loss for the fourth quarter ended December 31, 2023 was $18.6 million or $0.46 per share compared to $24.1 million or $0.61 per share for the fourth quarter ended December 31, 2022.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

Withdrawn application: Orencia, 19/02/2024

Retrieved on: 
Wednesday, April 3, 2024
CD86, Graft-versus-host disease, Gene, Methotrexate, Psoriasis, Letter, Cell, Bone marrow, Risk, Inflammation, Patient, Ageing, Psoriatic arthritis, HSCT, Allele, Joint, Protein, HLA, European Medicines Agency, Arthritis, Syringe, Rheumatism, Agency, Clinical trial, Skin, CD80, Cancer, Immune system, Blood, Calcineurin, Medicine, Vaccine

Withdrawn application: Orencia, 19/02/2024

Key Points: 


Withdrawn application: Orencia, 19/02/2024

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Retrieved on: 
Tuesday, February 6, 2024
Prostate cancer, Investigational New Drug, Cytokine, Immunotherapy, SITC, Clinical trial, NK, Society, Patient, IND, Good, Death, TSX, Allele, NKT, Therapy, Vaccine, Good manufacturing practice, HLA, Cancer, GMP, BCT

We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.

Key Points: 
  • We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
  • “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
  • BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
  • According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.

Pairwise Shares Advantages of Company-Developed Fulcrum™ Platform

Retrieved on: 
Thursday, February 1, 2024
Nature, USDA, Plant, Patent, RNA, Agriculture, Gene editing, Genetic variation, DNA, Genetics, Climate change, Food, Enzyme, SHARC, Allele, Bayer, IP, CRISPR, Breeding, Medicine, Organization

Durham, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Pairwise , a technology company pioneering genetics-based innovation in food and agriculture, shares multiple recent advances in its Fulcrum™ Platform .

Key Points: 
  • Durham, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Pairwise , a technology company pioneering genetics-based innovation in food and agriculture, shares multiple recent advances in its Fulcrum™ Platform .
  • Pairwise creates and uses advanced CRISPR-based tools like base editing and templated editing to create the desired level of genetic optimization,” said Ryan Bartlett, Pairwise Chief Technology Officer.
  • A complete suite of these novel technologies and proprietary tools for applying CRISPR technology make up the Fulcrum Platform, and enable Pairwise to unlock unique, commercially viable products with differentiated plant genetics.
  • As an important demonstration of the Pairwise Fulcrum Platform, the company introduced the first CRISPR-edited food to the food service channel and a retail test market in North America.

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
PD-L1, Research, A11, Ono Pharmaceutical, A24, Disease, WT1, Clinical trial, Epitope, Patient, Autoimmune disease, Allele, Pembrolizumab, Neoplasm, DCR, ORR, Ovarian cancer, SITC, Stomach, Cancer, Society, Vaccine, Pharmaceutical industry, Cryptocurrency

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023.

Key Points: 
  • BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023.
  • Presented positive data from ongoing Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting (SITC 2023) held November 1-5.
  • Completed enrollment of 20 patients for the ongoing Phase 1b study of CUE-101 in combination with pembrolizumab.
  • The Company reported collaboration revenue of approximately $3.7 million and $1.1 million for the nine months ended September 30, 2023 and 2022, respectively.

ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board

Retrieved on: 
Tuesday, December 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Biophysics, NIAID, TCR, Organization, Allen Institute, Executive Committee, National Cancer Institute, Cell Reports, University, Chan Zuckerberg Initiative, Master of Mathematics, Multimedia, Computational biology, Systems biology, Biomedicine, Allele, SAB, Machine learning, HLA, COVID-19, Kidney, Therapy, Intramural sports, NIH, World Allergy Organization, Cancer, Bangladesh Technical Education Board, CHI, Harvard University, Biomedical engineering, System, Digestive, Bachelor of Applied Science, Infection, Medical device, Management, Yale University, Columbia

ImmunoScape , a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB).

Key Points: 
  • ImmunoScape , a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB).
  • Dr. Tsang joins a distinguished group of leading scientists in immunology and oncology who help to guide ImmunoScape’s scientific strategy.
  • Dr. Tsang was also the Co-Director of the Trans-NIH Center for Human Immunology (CHI) and led its research program in systems human immunology.
  • Dr. Tsang has won multiple awards for his research, including several NIH/NIAID Merit Awards recognizing his scientific leadership in systems immunology, COVID-19, and human immunology research.

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Sunday, December 10, 2023
Research, FDA, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, Cytokine, PST, ASH, AUC, ACET, PD, Stem cell factor, Patient, CD19, Tmax, Allele, HLA, Cancer, Cmax, NHL, Pharmacodynamics, Investigator's brochure, Pharmaceutical industry, Vaccine, Medical imaging, Generic drug, Persistence

The data will be provided during a poster presentation at the ASH Annual Meeting on Sunday, December 10, 2023.

Key Points: 
  • The data will be provided during a poster presentation at the ASH Annual Meeting on Sunday, December 10, 2023.
  • “Historically, expansion and persistence of cell therapy products and release of functional cytokines have correlated with patient outcomes.
  • We remain on track to provide a clinical update from the Phase 1 study in NHL patients in the second half of 2024."
  • Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
    Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PST